From our partners at Organized Noise Keep reading to see why (MDCX) is topping our watchlist this morning—Tuesday, March 3rd, 2026.
 Dear Reader, Grand View Research projects the global basal cell carcinoma treatment market will hit USD $5.93B by 2030. Here's what stands out: the intralesional injections segment is expected to see the fastest growth. Right in the middle of this surging market sits a biotech company developing non-invasive skin cancer solutions while simultaneously pushing forward a next-generation hormone therapy that could transform treatment for advanced prostate cancer patients. Medicus Pharma Ltd. (NASDAQ: MDCX) tops our watchlist today—March 3rd, 2026. Here's what stands out: according to Yahoo Finance, (MDCX) has approximately 14.83M shares in its public float. Combined with a market cap around $38.75M, the potential exists for big moves if demand shifts. Keep in mind—when small floats meet potential catalysts, volatility could pop up in a flash. Medicus Pharma operates as a precision-guided biotech advancing two clinical-stage programs. SkinJect™ delivers doxorubicin through a proprietary dissolvable microneedle array for non-invasive BCC treatment. Teverelix® functions as a next-generation long-acting GnRH antagonist designed for advanced prostate cancer patients facing elevated cardiovascular risk. Recent Developments Worth Watching - SkinJect™ Phase 2 Fully Enrolled: The December 15 press release confirmed (MDCX) finished enrolling 90 patients across nine U.S. sites. Topline data drops Q1 2026.
- Teverelix® Gets FDA Green Light: Per the February 10 announcement, (MDCX) secured "study may proceed" clearance for its Phase 2b prostate cancer trial in high CV-risk patients.
- AI Collaboration Announced: According to the December 22 release, (MDCX) partnered with Reliant AI—staffed by ex-DeepMind/Google Brain engineers—to build clinical data analytics tools.
- Women's Health Data Unveiled: The January 12 press release revealed Phase 1 Teverelix® results in 48 women demonstrated favorable safety with stable bone turnover.
Positioned in Expanding Markets Grand View Research shows the BCC treatment space reaching $5.93B by 2030. Meanwhile, Fortune Business Insights forecasts prostate cancer hormone therapy climbing to $83.1B by 2034. Together, (MDCX) addresses roughly $8B in combined market potential. This is where it gets interesting for small-cap watchers. 3 Reasons (MDCX) Lands on Our Watchlist Today - Phase 2 Data Imminent: SkinJect™ topline results arrive Q1 2026—interim findings already demonstrated >60% clinical clearance.
- Fresh FDA Clearance: Teverelix® Phase 2b just got the green light, chasing a $6B+ combined market in CV-risk prostate cancer.
- AI-Powered Development: The Reliant AI partnership brings ex-DeepMind talent to enhance patient stratification and enrollment optimization.
According to Yahoo Finance—(MDCX) sits well below its 200-day moving average of $2.41, with a 52-week range of $0.92 to $8.94. From these levels, could we be looking at a reversal setup? Pull Up (MDCX) This Morning—Tuesday, March 3rd, 2026. With SkinJect™ Phase 2 data approaching and fresh FDA clearance for Teverelix®, (MDCX) enters a catalyst-heavy stretch. Analyst coverage points to significant upside, and the dual-asset pipeline targets large, global markets in oncology supportive care and hormone therapy. We have all eyes on (MDCX) this morning—Tuesday, March 3rd, 2026. Sincerely,
Sources: Market Data:
More Reading from MarketBeat Medtronic's "Textbook" Reversal: How High Can It Really Go in 2026?Authored by Thomas Hughes. Article Posted: 2/17/2026. 
Key Points - Medtronic is amid a market reversal that can double-digits to its stock price while it pays a market-beating dividend yield.
- Analyst and institutional activity highlight the value and yield combination, which is attractive compared to the broader market.
- Catalysts include improving operational efficiency and margin health, new product launches, and traction in robotics.
- Special Report: Trump's Hand-Written Letter Will Shock his Haters (From Paradigm Press)
 Medtronic's (NYSE: MDT) stock price is in the middle of a textbook reversal, having formed a Head & Shoulders pattern and broken to fresh highs, with the baseline confirmed as a key pivot. The question now is how high the stock might rise. The reversal is being supported by an improving growth outlook, stronger profitability, enhanced capital returns and improving market sentiment, which together provide a solid support base for 2026. 
Institutions and Analysts Buy Into Medtronic's Growth Outlook Fraud is being exposed everywhere right now. Billions gone.
But they're missing the big one...
A legal scam that affects 95% of ALL Americans.
Oxford Club's own Marc Lichtenfeld hit the streets of South Florida to expose it in broad daylight.
Watch along as he captures real people's reactions LIVE on camera. Click Here to Watch What Happens Institutions—which account for the largest portion of investment capital—own more than 80% of MDT and have been accumulating shares for several quarters. MarketBeat data shows a net bullish balance for five consecutive quarters, with roughly a $2-to-$1 bias toward buyers and buying activity that ramped up at year-end 2025 and into early 2026, in step with the stock's price action. If that bullish bias persists, MDT likely has further upside. Analysts—which often reflect private and retail sentiment—rate this stock as a Moderate Buy. Coverage has increased alongside an improving outlook, and the price-target trend was positive heading into fiscal Q3 (FQ3). (Note: Medtronic's fiscal reporting is offset from the calendar year.) Consensus forecasts imply roughly 10% upside, with additional upside at the high end of analyst estimates. Revision trends have been constructive and align with the stock's recent advance. While the FQ3 release and guidance update did not spark an immediate rally, the results were consistent with expectations that were already supporting the uptrend. Analyst sentiment should remain a supportive factor through the next quarter. Technical targets also converge with this outlook. With the reversal confirmed, technical projections use the range's dollar magnitude as the base case and a percentage move as the bull case. Those targets place MDT in the $118–$124 range, which brackets the high-end analyst target of $120. Timing remains the open question, but the charts suggest this move could occur before mid-year. Medtronic Affirms Long-Term Growth Targets: Outperforms in FQ3 Medtronic reported a solid quarter, with revenue of $9 billion that slightly outpaced consensus. Strength was broad-based, with roughly 6% organic growth, aided by foreign exchange tailwinds. Cardio was the standout segment—up nearly 14% (10.6% organically)—followed by 8.3% organic growth in Diabetes, 2.7% in Medical Surgical and 2.5% in Neurosciences. The company faced some margin headwinds, including tariffs, but there were no surprises materially worse than expected. Medtronic reported an adjusted operating margin of 24.1% and adjusted earnings per share (EPS) of $1.36, roughly in line with expectations. Management reaffirmed guidance, expecting revenue growth near 5.5% and full-year adjusted EPS of $5.64 at the midpoint. That guidance is slightly below consensus—about a one-cent shortfall at the midpoint—but the overall picture remains constructive. More important is the long-term outlook and the company's cash-flow profile, which supports continued capital return. The capital-return plan includes dividends and share repurchases; the dividend yield was about 2.8% as of mid-February, and buybacks are reducing the share count each year. With a payout ratio near 50% and a history of dividend increases, Medtronic is on a path that could see it join the Dividend Kings this decade. Medtronic: Many Catalysts in 2026 Medtronic has several catalysts that could drive further upside in 2026. Key segments, including cardiovascular, are accelerating, and new products and approvals—such as the Symplicity Spyral RDN system and the Hugo robotic systems—are contributing to growth. At the same time, activist investor pressure is pushing for operational improvements. The combined effect could produce outperformance in fiscal Q4, the full 2025 year and into 2026, with expanding margins and stronger capital returns. Elliott Investment Management emerged as a major shareholder in 2025 and is advocating for improved efficiency, faster growth and a higher valuation. Trading near 17X earnings, MDT looks inexpensive relative to the S&P 500 and med-tech peers. If the multiple expands toward peer averages—toward roughly 22X earnings—the stock could gain about five multiple points, implying a price near $125.
| 
